Muscle biopsies of patients with Inclusion Body Myositis (IBM) have demonstrated a T-cell
predominant inflammatory infiltrate, therefore, new agents targeting T -cell mediated cell
death may be a novel treatment for IBM. Such an agent capable of preventing T-cell movement
out of the vasculature, such as natalizumab, may be beneficial in IBM patients. Six patients
will be recruited to participate in this phase I trial.